KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) EBITDA: 2009-2024

Historic EBITDA for Emergent BioSolutions (EBS) over the last 16 years, with Dec 2024 value amounting to -$108.7 million.

  • Emergent BioSolutions' EBITDA rose 18.60% to $76.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.5 million, marking a year-over-year increase of 182.87%. This contributed to the annual value of -$108.7 million for FY2024, which is 85.04% up from last year.
  • As of FY2024, Emergent BioSolutions' EBITDA stood at -$108.7 million, which was up 85.04% from -$726.4 million recorded in FY2023.
  • Emergent BioSolutions' 5-year EBITDA high stood at $438.5 million for FY2020, and its period low was -$726.4 million during FY2023.
  • For the 3-year period, Emergent BioSolutions' EBITDA averaged around -$335.0 million, with its median value being -$170.0 million (2022).
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 284.31% in 2020, then slumped by 327.29% in 2023.
  • Yearly analysis of 5 years shows Emergent BioSolutions' EBITDA stood at $438.5 million in 2020, then dropped by 22.14% to $341.4 million in 2021, then slumped by 149.79% to -$170.0 million in 2022, then crashed by 327.29% to -$726.4 million in 2023, then skyrocketed by 85.04% to -$108.7 million in 2024.